23 February, 2006

Company Announcement

*Bioeffective A Receives Formal TGA Approval*

The Directors of Solagran Limited are pleased to announce that Australia’s Therapeutic Goods Administration has finalised its approval of Solagran’s *Bioeffective A* as a New Complementary Medicine Substance for both topical and internal use. The Directors consider this a major milestone for the Company.

*Bioeffective A*, the first member of the *Bioeffectives* product family originally developed in the late 1930s in Russia, will be known in Australia as Conifer Green Needle Extract or CGNC. Approval of CGNC means it can be incorporated into a virtually unlimited number of products.

Solagran’s efforts will now be focussed on the rapid commercialisation of *Bioeffective A*. The target segments include oral care, gastrointestinal health, antioxidant, cold & flu and topical creams for burns and wounds. Solagran expects to appoint a Director of Marketing to take charge of the commercialisation effort before the end of February.

As the next step in gaining wider regulatory approval, Solagran plans to lodge a New Dietary Ingredient application for *Bioeffective A* with the United States Food and Drug Administration (FDA).


Peter Stedwell

**Director**

On behalf of the Board of Directors